Minoo Ahmadinejad Explores Emicizumab
Minoo Ahmadinejad, Laboratory Director at Iranian Blood Transfusion Organization, shared on LinkedIn:
”Advances in hemophilia management had introduced novel therapies that challenged traditional approaches to laboratory monitoring.
Yesterday, I presented to medical doctors and specialists in hemato‑oncology on Emicizumab—a bispecific monoclonal antibody—and its impact on interpreting conventional coagulation assays.
Because standard tests such as aPTT and one-stage factor VIII activity appeared normalized.
The methods for measuring Emicizumab concentration needs modified specialized assays and measurements of FVIII activity or it’s inhibitor in the patient’s on Emicizumab treatment required chromogenic factor VIII tests with bovine reagents, for accurate assessment.
Through this discussion, I highlighted the key laboratory considerations, potential pitfalls, and strategies clinicians needed to adopt to ensure safe and effective patient care under this innovative treatment.”
Stay updated with Hemostasis Today.
-
Sep 30, 2026, 01:52Javed Anees: DADA2 – When a Young Stroke Is More Than a Stroke
-
Sep 30, 2026, 01:51How a Venous Thrombus Becomes Revascularized – ISTH
-
Sep 29, 2026, 22:45Victor Agunyego: Paracetamol – The Most Common Drug We Underestimate
-
Sep 29, 2026, 22:42Nova Sinclair: Advancing the Future of Hematology – Meet Our 2027 Organizing Committee
-
Sep 29, 2026, 22:41Lorenz Räber: Intracoronary Imaging in PCI – Why, When, How, and Which Modality?
-
Sep 29, 2026, 22:31Selma Turkovic: Pleased to Deliver the Opening Presentation at Kingston Hospital
-
Sep 29, 2026, 22:31Miguel Teran: Ultrasound and Simulation in Arterial Blood Sampling
-
Sep 29, 2026, 22:28Mohammad Refaei: Navigating Your Career in Hematology From Training to Practice
-
Sep 29, 2026, 22:27Matteo Foschi: 10 Clinical Pearls for Antithrombotic Therapy in Secondary Stroke Prevention